BioMarin Pharmaceutical (BMRN) Expected to Announce Earnings on Monday

BioMarin Pharmaceutical (NASDAQ:BMRN) is expected to be issuing its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect the company to announce earnings of $0.96 per share and revenue of $932.0320 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, August 3, 2026 at 4:30 PM ET.

BioMarin Pharmaceutical Price Performance

BMRN stock opened at $59.33 on Monday. BioMarin Pharmaceutical has a 1 year low of $49.26 and a 1 year high of $66.28. The company has a market cap of $11.47 billion, a P/E ratio of 43.31, a PEG ratio of 0.45 and a beta of 0.24. The firm has a 50-day moving average of $56.54 and a 200 day moving average of $56.82. The company has a debt-to-equity ratio of 0.23, a current ratio of 5.81 and a quick ratio of 4.20.

Wall Street Analysts Forecast Growth

BMRN has been the topic of a number of analyst reports. Morgan Stanley dropped their price target on BioMarin Pharmaceutical from $120.00 to $119.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 5th. Bank of America lowered their price objective on BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Wall Street Zen downgraded BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Citigroup increased their target price on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Finally, Royal Bank Of Canada reduced their price target on BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $88.26.

Insider Buying and Selling at BioMarin Pharmaceutical

In other news, EVP Gregory R. Friberg sold 3,281 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $53.85, for a total transaction of $176,681.85. Following the transaction, the executive vice president directly owned 51,818 shares of the company’s stock, valued at $2,790,399.30. This represents a 5.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.68% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of hedge funds have recently bought and sold shares of the business. Corient Private Wealth LLC grew its stake in shares of BioMarin Pharmaceutical by 159.5% in the fourth quarter. Corient Private Wealth LLC now owns 15,145 shares of the biotechnology company’s stock worth $900,000 after acquiring an additional 9,309 shares during the period. Mercer Global Advisors Inc. ADV boosted its holdings in BioMarin Pharmaceutical by 1.4% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 64,069 shares of the biotechnology company’s stock worth $3,808,000 after purchasing an additional 910 shares during the last quarter. EP Wealth Advisors LLC bought a new stake in BioMarin Pharmaceutical in the 4th quarter worth approximately $240,000. Krensavage Asset Management LLC grew its position in BioMarin Pharmaceutical by 29.4% in the 4th quarter. Krensavage Asset Management LLC now owns 524,786 shares of the biotechnology company’s stock worth $31,188,000 after purchasing an additional 119,336 shares during the period. Finally, Mackenzie Financial Corp raised its stake in BioMarin Pharmaceutical by 114.0% during the 4th quarter. Mackenzie Financial Corp now owns 375,067 shares of the biotechnology company’s stock valued at $22,082,000 after buying an additional 199,840 shares during the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.